SU101 signal transduction inhibitor data

SUGN reported interim results from an ongoing Phase I trial of SU101 at the American Society of Clinical Oncology meeting in Philadelphia. Patients in the dose escalation trial enroll in cohorts of three patients per dose level, and receive four weekly infusions of drug. Dosing began at 15 mg/m 2 and patients are now being treated at 188 mg/m 2 with no dose-limiting or dose-related toxicities yet observed.

To date, 24 patients with refractory brain cancer have completed their initial cycle of therapy. Of these, 13 patients have continued into extended therapy based on stable disease or better, as shown by physical exam and magnetic resonance imaging. Radiographic improvement has been observed in 3 patients. ...